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Edited by Lev KisselevAbstract Short-interfering RNAs (siRNAs) have proved to be a
useful tool in studying gene function in plants, invertebrates and
mammalian systems. Herein, we report the use of siRNAs for
targeting the human MAP kinase-interacting kinase Mnk1 gene.
This study demonstrates the eﬃcacy of the designed siRNA in
silencing Mnk1 in the human cell line HEK293T and shows that
Mnk1 suppression decreases eukaryotic initiation factor 4E
phosphorylation without causing any change in global protein
synthesis rate and cell proliferation. Interestingly, suppression of
Mnk1 results in a signiﬁcant increase in eukaryotic initiation
factor 4F complex formation after 72 h of transfection.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Translation1. Introduction
Translation is an important target for regulation of gene
expression in response to a large array of extracellular stimuli
playing a key role in controlling cell growth and proliferation.
A predominant step in translational regulation is the recruit-
ment of the 40S ribosomal subunit to the mRNA. This occurs
through 50 cap structure recognition (m7GpppX, where ‘‘X’’ is
any nucleotide) by the eukaryotic initiation factor 4F (eIF4F).
In higher eukaryotes, eIF4F consists of three subunits: eIF4E,
the cap-binding subunit, eIF4A, an ATP-dependent RNA
helicase, and eIF4G, that serves as a scaﬀold protein for as-
sembly of eIF4E and eIF4A into the eIF4F complex.
eIF4E is one of the main regulatory initiation factors be-
cause it is present in limiting molar amounts in the cell [1,2].* Corresponding author. Fax: +34-91-336-9016.
E-mail address: m.elena.martin@hrc.es (M. Elena Martın).
q When this paper was under revision, Ueda et al. [35] have published
the generation of mice lacking Mnk1, Mnk2 or both. In this paper, the
authors demonstrate that, even though eIF4E phosphorylation is not
detected, protein synthesis rate and development are not aﬀected.
These ﬁndings strongly support our results.
Abbreviations: 4E-BP, 4E-binding proteins; eIF, eukaryotic initiation
factor; ERK, extracellular signal-regulated kinase; IEF, isoelectric
focusing; MAP kinase, mitogen-activated protein kinase; Mnk, MAP
kinase-interacting kinase; siRNA, short-interfering RNA; SDS–
PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis;
RNAi, RNA interference
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following treatment of cells with growth factors, hormones and
mitogens [3–5]. It has also been found that inhibition of ex-
tracellular signal-regulated kinase (ERK) or p38 mitogen-ac-
tivated protein kinase (MAP kinase) pathways can inhibit the
phosphorylation of eIF4E [6]. MAP kinase-interacting kinase
1, Mnk1, [7,8] is phosphorylated and activated by Erk1/2 and
p38 MAP kinases both in vitro and in vivo [7,8] and phos-
phorylates eIF4E on Ser209 in vitro [8]. Studies conducted in
vivo suggest that Mnk1 is the physiological kinase of eIF4E
[6,9,10]. Nevertheless, there is conﬂicting evidence about the
role of eIF4E phosphorylation in translational control. Under
diﬀerent situations, a correlation exits between increased
phosphorylation and enhanced protein synthesis [11,12].
However, in others, eIF4E phosphorylation has no eﬀect
[13,14], or even induces a decrease in the rate of total protein
synthesis [15].
The eﬀect of eIF4E phosphorylation on eIF4F activity is
also controversial; thus, phosphorylated eIF4E was reported
to have higher binding aﬃnity for the cap [16] and to form a
more stable eIF4F complex [17]. However, another recently
published paper reported that eIF4E phosphorylation mark-
edly reduces its aﬃnity for capped mRNA [18]. In addition,
previous studies conducted to determine the role of human
Mnk1 in the cells have used several approaches such as over-
expression of Mnk1 and/or its constitutively active or inactive
mutants and the recently found speciﬁc inhibitor of Mnk1,
CGP57380 [15]. However, the use of either protein overex-
pression or pharmacological agents has the potential pitfall of
non-physiological or non-speciﬁc drug actions, respectively.
The double-stranded short-interfering RNAs (siRNA)-medi-
ated RNA interference (RNAi) is emerging as a powerful tool
to characterize gene function by genetic loss-of-function
analysis. This novel post-transcriptional gene silencing mech-
anism was ﬁrst demonstrated with great success in plants,
Caenorhabditis elegans, Drosophila and more recently in cul-
tured mammalian cells as well as in animal models [19–22].
Because of its high eﬃcacy, selectivity and ease of application,
we have investigated the functional importance of Mnk1 using
this more speciﬁc RNAi strategy.2. Materials and methods
2.1. T7 siRNA design and synthesis
Desalted DNA oligonucleotides were ordered from Sigma-Genosys
Ltd. Following the procedure described by Elbashir et al. [20], we
designed several double-stranded siRNAs to human Mnk1 with 30ation of European Biochemical Societies.
32 A. O’Loghlen et al. / FEBS Letters 578 (2004) 31–35overhanging uridine dimers. Target sequences were aligned to the
human genome database in a BLAST search to eliminate those with
signiﬁcant homology to other genes. The negative control for Mnk1
was designed scrambling the nucleotide sequence of the gene-speciﬁc
siRNA and was analyzed in a BLAST search to make sure it lacks
homology to any other gene. Four target sequences for Mnk1 gene
were selected for testing (see Fig. 1A). For each gene, siRNAs corre-
sponding to sequences located in the 50, 30, or central regions of each
transcript were deliberately chosen to assess whether diﬀerent regions
are more or less susceptible to siRNA induced degradation. siRNAs
were prepared by in vitro transcription using the Ambion Silencer
siRNA Construction Kit and quantiﬁed by standard techniques.
2.2. Cell cultures and RNA interference transfection
Human embryonic kidney (HEK293T) cells were maintained in 75-
cm2 tissue culture ﬂasks in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum in a humidiﬁed
5% CO2/95% air incubator at 37 C. HEK293T cells were subcultured
either in 24-well plates at a density of 104cells/well for cell viability and
protein synthesis rate determination, or in 6-well plates (5 104 cells/
well) for all other experiments. To suppress Mnk1 expression, cells
were transfected 48 h after plating using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA) following the supplier’s instructions.
Twenty or 100 pmol/well of siRNA in 24-well plates or 6-well plates,
respectively, was used.Fig. 1. Mnk1 suppression by siRNA. (A) Template sequences for
siRNA duplexes formation. A pair of sense and antisense templates
was designed to generate siRNA duplexes. The partial T7 promoter
sequence (underlined) was also included in each template. In vitro
transcription, annealing and puriﬁcation of siRNA duplexes were
performed using the protocol supplied with the silencer siRNA kit
(Ambion). (B) HEK293T were transfected with siRNA as described in
Section 2 and total lysates (60 lg) were resolved by 10% SDS–PAGE,
transferred onto PVDF membranes and immunoblotted with anti-
Mnk1(Ct) antibody. Bars represent the average of 1–3 diﬀerent ex-
periments. Data are expressed as the percentage of Mnk1 levels with
respect to siRNA-NS transfected cells (NS control) (set at 100%).2.3. Cell viability assay
We have measured cell viability by the methylthiazol tetrazolium
MTT reduction assay, as described elsewhere [23]. Brieﬂy, the mito-
chondrial function was determined by measuring the methylthiazol
tetrazolium (MTT) reduction ability of HEK293T under the diﬀerent
experimental conditions, using a Cell Proliferation Kit (Boehringer–
Mannheim [MTT]). MTT reduction was measured spectrophotomet-
rically at 540 nm.
2.4. Measurement of protein synthesis rate
Protein synthesis rate was assayed in 24-mm diameter multi-well
dishes with fresh medium containing 8 lCi/ml of [3H]methionine for 30
min at 37 C. Cells were harvested and the incorporation of methionine
into protein was determined by trichloroacetic acid precipitation as
described previously [23].
2.5. Cell lysates preparation
Cells cultured on 35-mm multi-well dishes were washed twice with
ice-cold buﬀer A (20 mM Tris–HCl, pH 7.6, 1 mM DTT, 1 mM
EDTA, 1 mM PMSF, 1 mM benzamidine, 2 mM sodium molybdate, 2
mM sodium b-glycerophosphate, 0.2 mM sodium orthovanadate, 120
mM KCl, 1 lg/ml leupeptin and pepstatin A, and 10 lg/ml antipain)
and lysed in the same buﬀer containing 0.5% NP-40 and 0.1% Triton
X-100. Cell lysate was centrifuged at 12 000· g for 10 min and the
supernatants were kept at )80 C until used. Protein determination
was performed by the Bradford method [24].
2.6. SDS–PAGE, isoelectric focusing and immunoblotting
Cell lysates (60 lg) were resolved by sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS–PAGE), at the conditions indi-
cated in the legends of ﬁgures, and analyzed by immunoblotting as
described previously [25]. Monoclonal GAPDH antibody was from
Ambion and anti-Mnk1 antibodies (against amino and carboxy ter-
minus) were obtained from Santa Cruz Biotechnology. To determine
eIF4E phosphorylated levels, cell lysates (50 lg) were resolved by
horizontal isoelectric focusing (IEF) slab gels and analyzed by im-
munoblotting as described [25]. Bands were scanned and quantiﬁed
with an image analyzer equipped with Diversity One software (PDI).
2.7. RT-PCR expression analysis
Mnk1a and Mnk1b mRNAs expression pattern was assayed by re-
verse transcription-PCR using the Access RT-PCR System (Promega)
as described elsewhere [26]. 10 and 50 ng of total RNA obtained from
untransfected (UC) or siRNA-NS and siRNA-M3 transfected cells
using TRIZOL Reagent (Invitrogen) were used as template. The
primers used in these reactions were 5MNK1b (50-
AAGGACTGGGCACAC-30) and 3MNK1 (50-GGCGAATTCTCA-
GAGTGCTGTGGGCGG-30). GAPDH mRNA and speciﬁc primers
were used as a control. Bands were scanned and quantiﬁed as above.
2.8. eIF4F activity
eIF4F complex formation was measured as the amount of eIF4G
recovered when eIF4E was puriﬁed using m7GTP–Sepharose as de-
scribed previously [25]. eIF4G and eIF4E levels in the complex were
detected by immunoblot analysis using a polyclonal anti-eIF4G anti-
body generously provided by Dr. S.J. Morley and the monoclonal anti-
eIF4E antibody (BD Biosciences) and quantiﬁed as above.3. Results and discussion
To determine the functional role of Mnk1 in the cells, ge-
netic loss-of-function analysis was performed using siRNA.
Four siRNAs were designed by targeting diﬀerent positions
within the coding region of the kinase (Fig. 1A) according to
the procedure described by Elbashir et al. [20]. As a negative
control, a non-speciﬁc siRNA (NS) was also designed. To
examine the ability of siRNAs to suppress endogenous Mnk1
expression, human embryonic kidney (HEK293T) cells were
transfected with siRNAs. Cell lysates were harvested 24, 48
and 72 h posttransfection and the levels of Mnk1 protein
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Mnk1 expression strongly decreased in cell transfected with
siRNA-M3 and siRNA-M29 (72% and 45%, respectively) after
48 h of transfection, while Mnk1 expression was not sup-
pressed in siRNA-M40 or siRNA-M60 transfected cells. No
additional silencing eﬀect was observed in siRNA-M3 and
siRNA-M29 transfected cells after 72 h of transfection. Thus,
siRNA-M3 was chosen for the study.
To test both the speciﬁcity and eﬃcacy of siRNA-M3, we
have used siRNA-NS and untransfected cells as controls.
Mnk1 expression decreased signiﬁcantly in siRNA-M3 trans-
fected cells with respect to untransfected or siRNA-NS
transfected cells after 48 and 72 h of transfection (Fig. 2A and
B). We have recently identiﬁed a splice variant of human
Mnk1 which has been named as Mnk1b. Human Mnk1b
mRNA is homologous to human Mnk1 mRNA but lacks a
region corresponding to exon 19, which causes a change in the
reading frame generating a stop codon [26]. Because the re-
sulting protein lacks the last 89 amino acids at the C-terminal
region that are replaced by 12 amino acids with an entirely new
sequence, this variant cannot be detected with the antibody
against C-terminal region of human Mnk1 [26]. We have
checked Mnk1b levels in siRNA-M3 and siRNA-M29 trans-
fected cells with the antibody against the N-terminal end of
Mnk1, which detects both isoforms a and b. As expected, a 30–
40% reduction in Mnk1b levels was also observed with bothFig. 2. Mnk1 suppression in HEK293T cells transfected with siRNA-
M3. (A) Mnk1 expression in cells transfected with siRNA-M3 was
determined as in Fig. 1B. siRNA-NS transfected and untransfected
(UC) cells were used as controls. A representative blot from several
experiments is shown. As a control of loading, the membranes were
reprobed with b-actin antibody. (B) Quantiﬁcation of the Mnk1 levels.
Bars represent means S.E.M. of four diﬀerent experiments. Data are
expressed as the percentage of Mnk1 levels with respect to NS control
(set at 100%). Statistical signiﬁcance (calculated by Student’s t test)
compared to NS control, **P < 0:01. (C) Mnk1b expression in cells
transfected with siRNA-M3 and siRNA-M29 was determined by im-
munoblotting at 48 h posttransfection using anti-Mnk1 (Nt) antibody.
Membranes were reprobed with anti-GAPDH for control of loading.
Numbers at the bottom of the ﬁgure show the percentage of Mnk1b
with respect to NS control (set at 100%). The ﬁgure shows a repre-
sentative experiment. Similar results were obtained in three separate
experiments. (D) RT-PCR analysis of Mnk1a and Mnk1b mRNAs
expression was performed using total RNA (10 and 50 ng) from siR-
NA-NS and siRNA-M3 transfected cells and untransfected cells.
GAPDH mRNA levels were used as control. Bands were quantiﬁed
and the average values (ODmm2) from two separate experiments are
shown at the bottom of the ﬁgure. Keys: Untransfected cells (UC);
cells transfected with siRNA-NS (NS), siRNA-M3 (M3), siRNA-M29
(M29).siRNAs (Fig. 2C). RT-PCR analysis of Mnk1a and Mnk1b
mRNAs also revealed a 40% reduction in Mnk1a/b mRNA
levels with siRNA-M3 treatment as compared to both siRNA-
NS treatment and untransfected cells (Fig. 2D), indicating that
siRNA-M3 eﬀectively degrades Mnk1 transcripts, which sub-
sequently reduces Mnk1 expression. Altogether, the above
results demonstrate that the siRNA designed is speciﬁc against
human Mnk1.
Next, we have studied the eﬀect of the reduction in the level
of Mnk1 on eIF4E phosphorylation, protein synthesis rate, cell
proliferation and eIF4F activity. Up to date, four Mnks hu-
man eIF4E kinases have been characterized, Mnk1a, Mnk1b,
Mnk2a and Mnk2b [7,8,26,27]. Because Mnk2a and Mnk1b
have very high cellular basal activities, they are likely to have
important consequence for cellular levels of phosphorylated
eIF4E and could mask our results [26,28]. However, the low
phosphorylated eIF4E levels in HEK293T cells [26] suggest a
low abundance of Mnk2a and Mnk1b and make this cell line a
good candidate for our studies. Besides, as far as Mnk1b levels
are concerned, we demonstrated that they signiﬁcantly de-
creased in siRNA-M3 transfected cells in parallel with the
decrease observed in Mnk1a levels (Fig. 2). Mnk1 downregu-Fig. 3. Eﬀect of Mnk1 suppression on eIF4E phosphorylation (A and
B), protein synthesis rate (C) and cell proliferation (D). (A) Cell lysates
(50 lg) of HEK293T cells previously transfected with siRNA-NS or
siRNA-M3 or untransfected cells (UC) were obtained as described in
Section 2 and subjected to IEF. Bands corresponding to unphos-
phorylated eIF4E (eIF4E) and phosphorylated eIF4E (eIF4EP) were
analyzed by protein immunoblot as described in Section 2. Blot is
representative of a typical experiment. (B) Results are expressed as
percentage of eIF4E P over total eIF4E and represent meansS.E.M.
of 3–5 diﬀerent experiments. Statistical signiﬁcance compared to NS
control, **P < 0:01. (C) Protein synthesis rate was determined as de-
scribed in Section 2. Results are expressed as the percentage of NS
control values and represent means SEM of three diﬀerent experi-
ments. (D) Cell proliferation was determined at 48 and 72 h post-
transfection as described in Section 2. Data are expressed in arbitrary
units and represent the meansS.E.M. of four diﬀerent experiments.
No diﬀerences were observed in protein synthesis rate (C) and cell
proliferation (D) between untransfected cells and siRNA-NS or siR-
NA-M3 transfected cells (not shown).
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eIF4E phosphorylation (Fig. 3A and B), but it did not have
any eﬀect on protein synthesis rate (Fig. 3C). This ﬁnding is in
accordance with the notion that eIF4E phosphorylation does
not seem to be essential for the activation of global translation
[29]. Cell proliferation, as measured by MTT reduction, was
not aﬀected by Mnk1 suppression as well (Fig. 3D), consistent
with the ﬁndings of Knauf et al. [15] that show no eﬀect on cell
proliferation when Mnk1 is inhibited by CGP57380.
The role of eIF4E phosphorylation on eIF4F activity re-
mains to be elucidated. In HEK293 cells, the increased eIF4F
activity induced by the phorbol ester 12-O-tetradecanoyl-
phorbol-13-acetate correlates with an increase in eIF4E
phosphorylation, while insulin, which also enhances eIF4F
formation, does not increase eIF4E phosphorylation [30].
Moreover, several studies have shown that increased eIF4E
phosphorylation caused by overexpression of Mnk1 does not
induce any change in eIF4E/eIF4G complex formation
[15,30,31], but slightly decreases total protein synthesis rate
[15,31]. Thus, it is hypothesized that the sustained increase in
eIF4E phosphorylation may induce a decreased cap-bindingFig. 4. Eﬀect of Mnk1 suppression on eIF4F complex formation. (A)
Cell lysates (100 lg) of HEK293T cells, previously transfected with
siRNA-NS or siRNA-M3 during 48 or 72 h, and untransfected cells
were subjected to m7GTP–Sepharose chromatography following im-
munoblot using antibodies against eIF4E and eIF4G. Blots, corre-
sponding to two diﬀerent cultures, show eIF4G and eIF4E bound to
m7GTP–Sepharose (upper panel). No diﬀerences were found for eIF4E
bound to resin (92.2 6.2, 81.3 14.8 and 84.5 20.2 A.U., for un-
transfected cells (UC), siRNA-NS and siRNA-M3 transfected cells,
respectively). Total levels of eIF4G and eIF4E corresponding to 50%
input are shown (lower panel). (B) eIF4F complexes were measured as
the ratio between eIF4G and eIF4E and were compared to the ratio in
NS control cells, which was deﬁned as 1. Bars represent the means
S.E.M. of four diﬀerent experiments. Abbreviations and statistical
signiﬁcance are as in Figs. 2 and 3, *P < 0:05.aﬃnity [18,32]. We have examined the eﬀect of Mnk1 sup-
pression on eIF4F activity by measuring the amount of eIF4G
recovered when eIF4E was puriﬁed using m7GTP–Sepharose.
As shown in Fig. 4, eIF4G bound to eIF4E in cells transfected
with siRNA-M3 increased with respect to that found in siR-
NA-NS, being signiﬁcant after 72 h posttransfection. How-
ever, although total eIF4E and eIF4G levels in transfected cells
slightly decreased with respect to untransfected cells (10% and
25%, respectively), no changes between siRNA-NS and siR-
NA-M3 transfected cells were observed (Fig. 4A). Our results
support the hypothesis that the sustained dephosphorylation
of eIF4E induced by Mnk1 suppression might generate a
slower turnover of eIF4E on capped mRNA, resulting in an
increased eIF4F complex formation. In fact, studies from our
laboratory performed in primary neuronal culture show that
IGF-1 activates eIF4F complex formation in parallel with a
decrease in eIF4E phosphorylation levels [33]. eIF4E may not
be the only Mnk1 substrate, in fact, eIF4G appears to be a
substrate of Mnk1 [34]. Consequently, the dephosphorylation
of other Mnk1 substrates possibly involved in eIF4F forma-
tion should not be discarded. Increased eIF4F activity could
get the cells ready for changing the program of synthesized
proteins in response to the diﬀerent stimuli, i.e., by allowing
the translation of speciﬁc transcripts with long and highly
structured 50 untranslated regions, which are extremely de-
pendent on high eIF4F levels.
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